Granted Patent
B2
US 12,257,306 · App. 18/050,351 · Granted Mar 25, 2025
Antiviral prodrugs and nanoformulations thereof
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides prodrugs and methods of use thereof.
Claims (11)
1. A compound, or a pharmaceutically acceptable salt or stereoisomer thereof, comprising:
(a) a first bictegravir molecule;
(b) a second bictegravir molecule; and
(c) a linker, wherein the linker covalently attaches the first and second bictegravir molecules.
2. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the linker is a diester comprising a saturated linear aliphatic chain of 16 carbons in length in between the ester of the diester, wherein the number of carbons does not include the carbon in the C═O of each ester of the diester, and wherein the hydroxy of each bictegravir is replaced by said ester of the diester.
3. A nanoparticle, comprising: (a) a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and (b) a polymer or surfactant.
4. The nanoparticle of claim 3 , wherein said polymer or surfactant is an amphiphilic block copolymer.
5. The nanoparticle of claim 4 , wherein said amphiphilic block copolymer comprises at least one block of poly(oxyethylene) and at least one block of poly(oxypropylene).
6. The nanoparticle of claim 3 , wherein said polymer or surfactant is P407.
7. The nanoparticle of claim 3 , wherein said polymer or surfactant is polysorbate or polyethylene glycol.
8. A pharmaceutical composition, comprising: (a) a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and (b) a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2022
From: GENDELMAN, HOWARD E.; EDAGWA, BENSON
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 062157/0262 →
Continuity (3)
Continuation
17309435
Provisional Application
62772852
· Nov 29, 2018
References Cited (68)
US 9216996B2
· Jin et al.
· 2015
[cited by applicant]
US 9758515B2
· Takahashi et al.
· 2017
[cited by applicant]
US 20130171214A1
· Mundhra et al.
· 2013
[cited by applicant]
US 20140011995A1
· Sumino et al.
· 2014
[cited by applicant]
US 20140221378A1
· Miyazaki et al.
· 2014
[cited by applicant]
US 20150050241A1
· Volinsky et al.
· 2015
[cited by applicant]
US 20160184332A1
· Renner
· 2016
[cited by applicant]
US 20220175936A1
· Gendelman et al.
· 2022
[cited by applicant]
WO WO2010011814A1
· 2010
[cited by applicant]
WO WO2012061480A2
· 2012
[cited by applicant]
WO WO2014200880A1
· 2014
[cited by applicant]
WO WO20170223280A2
· 2017
[cited by applicant]
WO WO2020086555A1
· 2020
[cited by applicant]
WO WO2020112931A1
· 2020
[cited by applicant]
WO WO2022099431A1
· 2022
[cited by applicant]
Co-Pending U.S. Appl. No. 17/301,030, filed Mar. 22, 2021.
[cited by applicant]
Co-Pending U.S. Appl. No. 17/303,228, filed May 24, 2021.
[cited by applicant]
Co-Pending U.S. Appl. No. 17/303,229, filed May 24, 2021.
[cited by applicant]
Dolutegravir, Wikipedia (5 pages) (2023).
[cited by applicant]
EP Search Report EP 23 16 0610, dated Aug. 8, 2023 (3 pages).
[cited by applicant]
EP Search Report EP 23 16 0303, dated Aug. 9, 2023 (3 pages).
[cited by applicant]
Goldstein et al., “Incidence of class 1 and class 2 integrases in clinical and commensal bacteria from liverstock, Companion animals and exotics,” Antimicrobial Agents and Chemotherapy, vol. 45(3): 723-726 (2001).
[cited by applicant]
Integrase, Wikipedia (5 pages) (2023).
[cited by applicant]
Retrovirus, Wikipedia (7 pages) (2023).
[cited by applicant]
Andrews, C.D., et al., A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge, Sci Transl Med, 7(270): 270ra4 (2015).
[cited by applicant]
Andrews, C.D., et al., Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus, Science, 343(6175): 1151-1154 (2014).
[cited by applicant]
Application of Harold G. Petering and Harry H. Fall, Patent Appeal No. 6750, United States Court of Customs and Patent Appeals, Apr. 13, 1962.
[cited by applicant]
Edgawa, B., et al., Long acting slow effective release antiretroviral therapy, Expert Opin Drug Deliv, 14(11): 1281-1291 (2017).
[cited by applicant]
Gautam, N., et al., Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir, Nat Commun, 12(1): 3453 (2021).
[cited by applicant]
Gendelman, H.E., et al., The promise of long acting antiretroviral therapies: From need to manufacture, Trends Microbiol, 27(7): 593-606 (2019).
[cited by applicant]
Ikuta, Y., et al., The effect of molecular structure on the anticancer drug release rate from prodrug nanoparticles, Chem Commun (Camb), 51(64): 12835-12838 (2015).
[cited by applicant]
Kulkarni, T.A., et al., A year-long extended release nanoformulated cabotegravir prodrug, Nat Mater, 19(8): 910-920 (2020).
[cited by applicant]
Landovitz, R.J., et al., Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial, PLoS Med, 15(11):e1002…
[cited by applicant]
Long, Y., et al., Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase, J Med Chem, 47(10): 2561-2…
[cited by applicant]
Margolis, D.A., et al., Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial, Lancet, 390(10101): …
[cited by applicant]
Markowitz, M., et al., Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial, Lancet HIV, 4(8): e331-e…
[cited by applicant]
McMillan, J., et al., Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques, AIDS, 33(3): 585-588 (2019).
[cited by applicant]
McMillan, J., et al., Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques, Antimicrob Agents Chemother, 62(1): e01316-e01317 (2018).
[cited by applicant]
Namanja, H.A., et al., Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers, J Am Chem Soc, 134(6): 2976-2980 (2012).
[cited by applicant]
PCT/US2017/038693 International Search Report and Written Opinion dated Nov. 27, 2017.
[cited by applicant]
PCT/US2019/057406 International Search Report and Written Opinion dated Jan. 16, 2020.
[cited by applicant]
PCT/US2019/063498 International Search Report and Written Opinion dated Apr. 8, 2020.
[cited by applicant]
Radzio, J., et al., The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge, Sci Transl Med, 7(270): 270ra5 (2015).
[cited by applicant]
Sillman, B., et al., Creation of a long-acting nanoformulated dolutegravir, Nat Commun, 9(1): 443 (2018).
[cited by applicant]
Spreen, W., et al., GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects, J Acquir Immune Defic Syndr, 67(5): 481-486 (2014).
[cited by applicant]
Spreen, W.R., et al., Long-acting injectable antiretrovirals for HIV treatment and prevention, Curr Opin Hiv Aids, 8(6): 565-571 (2013).
[cited by applicant]
Stellbrink, H-J, et al., Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis, Curr Opin Hiv Aids, 13(4): 334-340 (2018).
[cited by applicant]
Trezza. C.,et al., Formulation and pharmacology of long-acting cabotegravir, Curr Opin Hiv Aids, 10(4): 239-245 (2015).
[cited by applicant]
U.S. Appl. No. 17/301,030 Office Action dated May 27, 2021.
[cited by applicant]
U.S. Appl. No. 17/303,228 Office Action dated Aug. 11, 2021.
[cited by applicant]
U.S. Appl. No. 17/303,229 Office Action dated Aug. 25, 2021.
[cited by applicant]
Zaro, J.L., et al., Lipid-based drug carriers for prodrugs to enhance drug delivery, Aaps J, 17(1): 83-92 (2015).
[cited by applicant]
Zhou, T., et al., A long-acting nanoformulated cabotegravir prodrug for improved antiretroviral therapy, Topics in Antiviral Medicine, 25(Supplement 1): 180s-181s, Abstract Number: 439. EMBASE Document No. 616686282 (20…
[cited by applicant]
Zhou, T., et al., Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles, Biomaterials, 151: 53-65 (2018).
[cited by applicant]
Zhou, T., Next generation of trasnslational long-acting cabotegravir, Electronic Theses and Dissertations University of Nebraska Medical Center, 139 pages (2018).
[cited by applicant]
Soriano et al., Long-acting antiretroviral therapy, Nature Materials, vol. 19:826-827 (2020).
[cited by applicant]